Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Active not recruiting 8Recruiting 6Completed 5Unknown 2Terminated 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 13Dermatologic 3CNS 3Thoracic 2Plasma cell 2Head & Neck 2Gastrointestinal 2Tumor-Agnostic 1Sarcoma 1Other solid neoplasm 1Other hematologic neoplasm 1Myeloid 1Lymphoid 1Gynecologic 1Endocrine 1Classical hematology 1Breast 1

Conditions

Thyroid cancer, medullary 1Thyroid Neoplasms 1Thyroid Diseases 1Thyroid Cancer, Papillary 1Carcinoma, Medullary 1Adenocarcinoma, Follicular 1

Interventions

Everolimus 10lanreotide 4Capecitabine 4pasireotide 3lutetium Lu 177 dotatate 3lenvatinib 3fosbretabulin 3Temozolomide 3Sorafenib 3Paclitaxel 3Octreotide 3Nivolumab 3Magnetic Resonance Spectroscopy 3Filgrastim 3Erlotinib Hydrochloride 3Doxorubicin 3trifluridine tipiracil drug combination 2surufatinib 2pembrolizumab 2pegfilgrastim 2gallium Ga 68 dotatate 2durvalumab 2dactolisib 2Surveys and Questionnaires 2Surgical Procedures, Operative 2Sunitinib 2Rosiglitazone 2Radiotherapy 2Panobinostat 2Mitotane 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Terminated × cabozantinib × Endocrine × Clear all
NCT03630120 2021-07-14

Adaptive Tyrosine Kinase Inhibitor (TKI) Therapy In Patients With Thyroid Cancer

H. Lee Moffitt Cancer Center and Research Institute

Phase 2 Terminated
6 enrolled 9 charts
EndocrineHead & Neck

Thyroid cancer, medullary, Thyroid Cancer, Papillary, Thyroid Diseases, Thyroid Neoplasms, Adenocarcinoma, Follicular, Carcinoma, Medullary

Data powered by HemOnc (CC BY 4.0) Colophon âš¡